12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-SMNRx: Phase I started

Isis began an open-label, dose-escalation, U.S. Phase I trial to evaluate 4 doses of intrathecal ISIS-SMNRx in about 24 patients ages 2-14...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >